Young Eun Chon, Dong Joon Kim, Sang Gyune Kim, In Hee Kim, Si Hyun Bae, Seong Gyu Hwang, Jeong Heo, Jeong Won Jang, Byung Seok Lee, Hyung Joon Kim, Dae Won Jun, Kang Mo Kim, Woo Jin Chung, Moon Seok Choi, Jae Young Jang, Hyung Joon Yim, Won Young Tak, Ki Tae Yoon, Jun Yong Park, Kwang-Hyub Han, Ki Tae Suk, Hyun Woong Lee, Byoung Kuk Jang, Sang Hoon Ahn
Currently, limited data are available regarding the efficacy and safety of pegylated interferon alpha-2a (PEG-IFN α-2a) in Korean patients with chronic hepatitis B (CHB), in whom hepatitis B virus (HBV) genotype C is the most common type.We collected data from 439 patients (HBeAg positive, n = 349; HBeAg negative, n = 90) with CHB who were treated with PEG-IFN α-2a as a first-line therapy from 18 institutions. Treatment responses at the end of treatment (ET) and at 6 months posttreatment (PT6) were compared between the patients who were treated for 24 weeks versus 48 weeks, and adverse events (AEs) were evaluated...
April 2016: Medicine (Baltimore)